Mobile App

Google Play Apple Store
Conversations in Relapsed/Refractory Multiple Myeloma: Strategies to Effectively Introduce, Optimize, and Sequence Bispecific Antibody Therapy
AMA/ABS/ANCC/ACPE Activity- Podcast Series
Patients with relapsed/refractory multiple myeloma (RRMM) are associated with poor survival outcomes and are in continual need of more effective therapies. Currently, a multitude of agents including monoclonal antibodies, proteosome inhibitors, immunomodulatory agents, bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and selinexor are available for patients with RRMM. More recently, the bispecific antibodies, teclistamab, elranatamab, and talquetamab have been approved for the treatment of RRMM and are also under investigation in combination with other agents and in different settings of MM.

In this podcast series, leading experts summarize the rationale/mechanism of action and clinical evidence on approved and emerging bispecific antibody therapy in RRMM and aid participants in using these agents safely by using clinical vignettes. The activity also provides guidance on early recognition of key adverse events and strategies to manage them, to ultimately improve outcomes for patients with RRMM.
Review the activity and claim AMA/ABS/ANCC/ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.

Jesús G. Berdeja, MD Jesús G. Berdeja, MD
Director of Multiple Myeloma Research
The Greco-Hainsworth Tennessee Oncology Centers for Research

Joseph Mikhael, MD, MEd, FRCPC, FACP Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University

Saad Usmani, MD Saad Usmani, MD
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center

Supported by an independent educational grant from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Launch Date: May 2, 2024
Release Date: May 2, 2024
Expiration Date: April 30, 2025

Mini Module


Change Settings